<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Idiopathic pure red-cell <z:mpath ids='MPATH_58'>aplasia</z:mpath> was successfully treated by high-dose intravenous immunoglobulin infusions (HDivIg) in 2 patients; 1 of these patients was refractory to other immunosuppressive drugs </plain></SENT>
<SENT sid="1" pm="."><plain>We have observed responses to this therapy also in 3 of 5 patients--without pretreatment--with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>HDivIg treatment had no significant side effects; patients with aplastic syndromes could be treated as outpatients </plain></SENT>
<SENT sid="3" pm="."><plain>Patients responding to HDivIg demonstrated different response patterns to <z:chebi fb="0" ids="4031">ciclosporin</z:chebi> A </plain></SENT>
<SENT sid="4" pm="."><plain>Sequential treatment of aplastic syndromes with high-dose <z:chebi fb="0" ids="8382">prednisone</z:chebi>, HDivIg and <z:chebi fb="0" ids="4031">ciclosporin</z:chebi> A was effective in 6 of 7 patients </plain></SENT>
<SENT sid="5" pm="."><plain>The results in this pilot study are comparable to those with other immunosuppressive strategies in patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> who lack a bone marrow donor </plain></SENT>
<SENT sid="6" pm="."><plain>Optimal dosage, sequence, and duration of this treatment modality remain to be defined </plain></SENT>
</text></document>